Early phase-2 trials are already underway in the United States assessing the efficacy of both sotorasib and adagrasib in the neoadjuvant setting for KRAS G12C mutant lung cancers, including neoadjuvant therapy for 6 weeks of adagrasib with placebo or nivolumab (NCT05472623) [76] and neoadjuvant therapy for four cycles of platinum-based chemotherapy and sotorasib (NCT05118854) [77]. This evidence concerns the gene KRAS and lung carcinoma.